Calyxha Biotechnologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Calyxha Biotechnologies is a preclinical-stage biotech leveraging a computational discovery platform to develop novel small molecule anti-inflammatory drugs. Its lead asset, CAL-4, is a calixarene-based compound designed to mimic heparan sulfate, aiming to provide steroid-like efficacy without the associated side-effect pathways. Initially targeting asthma via inhalation, CAL-4 is slated for clinical entry in 2025, with potential expansion into COPD, neurodegenerative diseases, and allergy. The company is led by a small, experienced team of entrepreneurs and scientists.

InflammationRespiratoryNeurology

Technology Platform

Computational drug discovery platform integrating multiple software tools and biological pathway analysis to design small molecule calixarene-based drugs that mimic the anti-inflammatory function of heparan sulfate.

Opportunities

The primary opportunity is addressing the massive unmet need for a safe, steroid-sparing therapy in multi-billion dollar markets like asthma and COPD.

Success in the lead indication could enable rapid expansion into other inflammatory conditions, including high-value areas like neuroinflammation associated with neurodegenerative diseases.

Risk Factors

The company faces high scientific risk as its novel, unproven mechanism may not translate to human efficacy or safety.

Financial risk is acute, as it is pre-revenue and entirely dependent on raising capital to fund expensive clinical trials.

Pipeline concentration risk is extreme, with the company's value tied to a single preclinical asset.

Competitive Landscape

Calyxha operates in the highly competitive inflammation space, competing against large pharma's steroid franchises, next-generation biologics (e.g., anti-IL-5, anti-IgE), and other small molecule developers. Its differentiation hinges on proving CAL-4's unique safety profile versus corticosteroids, a significant but challenging hurdle.

More companies in Small Molecule Drugs →More companies in Austria →